Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (pericytes) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 14890
Sealed predictions
- CCL19 in dopamine neurons, braak-0.29 (p 0.456) → -0.46 (p 0.209)receipt 14899
Swarm cases
receipt 14899: CCL19 in dopamine neurons, braak
- power
- full sample -0.37 (p 0.127, n 18), 95% CI -0.72 to +0.11. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.37 (p 0.127, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.58 (p 0.011, n 18). not the mix.
- skeptic
- leave-one-out range -0.53 to -0.29, sign flips 0; without severely affected donors -0.37 (p 0.127, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCL19 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts